VTP50469 was the first small-molecule inhibitor of the menin-KMT2A interaction; treatment of KMT2A-rearranged leukemia cell lines and primary samples with this agent led to downregulation of the classic KMT2A gene signature and prolonged survival (even cures) in mice [153]. Here, KMT2A is linked to leukemia.